Intradermal fractional dose inactivated polio vaccine: A review of the literature

Nelson, Katherine S.; Janssen, Julia M.; Troy, Stephanie B.; Maldonado, Yvonne

doi:10.1016/j.vaccine.2011.11.018

Cited by 48 publications

(32 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…39 Furthermore, no cases of type 3 wild poliovirus have been reported since a 2012 case in Nigeria, although type 1 wild poliovirus is still circulating in Pakistan and Afghanistan. 39 Replacement of oral poliovirus vaccine (OPV) with IPV seems to be essential for global eradication of polio, 21 because OPV has the potential to regain pathogenicity and cause vaccine-derived poliovirus paralysis. 40 Indeed, the globally Advisory Group of Experts on Immunization.…”

Section: Poliovirus Vaccinementioning

confidence: 99%

“…Jet injectors are needle-free devices that use a gas propulsion system to deliver vaccine by an ID, IM, or SC route. 21 Needle-free devices, which were used in five (71%) of these seven studies, may reduce costs when switching from OPV to IPV in resource-limited areas. 45 Some reports showed similar seroconversion rates but lower antibody titers after ID delivery, as compared with IM injection; 41,46 other studies showed that a one-fifth dose ID vaccination was inferior to a full-dose IM vaccination.…”

Section: Poliovirus Vaccinementioning

confidence: 99%

See 1 more Smart Citation

Intradermal vaccination for infants and children

Saitoh

Aizawa

2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Intradermal (ID) vaccination induces a more potent immune response and requires lower vaccine doses as compared with standard vaccination routes. To deliver ID vaccines effectively and consistently, an ID delivery device has been developed and is commercially available for adults. The clinical application of ID vaccines for infants and children is much anticipated because children receive several vaccines, on multiple occasions, during infancy and childhood. However, experience with ID vaccines is limited and present evidence is sparse and inconsistent. ID delivery devices are not currently available for infants and children, but recent studies have examined skin thickness in this population and reported that it did not differ in proportion to body size in infants, children, and adults. These results are helpful in developing new ID devices and for preparing new vaccines in infants and children.

show abstract

Section: Poliovirus Vaccinementioning

confidence: 99%

Section: Poliovirus Vaccinementioning

confidence: 99%

Intradermal vaccination for infants and children

Saitoh

Aizawa

2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Therefore, intradermal administration of antigens is believed to be more effective compared to intramuscular administration. Clinical trials with intradermal delivery of a fractional dose of IPV demonstrated that this is indeed the case, but the dose-sparing effect fell short of the target 1/5 of the intramuscular dose (Resik et al 2010;Cadorna-Carlos et al 2012;Nelson et al 2012;Soonawala et al 2013). Effective priming immunization after one intradermal dose of IPV was demonstrated by an anamnestic response to a booster dose of the vaccine (Resik et al 2013).…”

Section: New Generation Of Polio Vaccinesmentioning

confidence: 98%

Current Status and Future of Polio Vaccines and Vaccination

Chumakov

2014

Novel Technologies for Vaccine Development

View full text Add to dashboard Cite

The history of polio vaccines and their use illustrates the concept of evolution of vaccines driven by changing epidemiological and socioeconomic conditions. The development of two vaccines against poliomyelitis-inactivated Salk vaccine (IPV) and live oral Sabin vaccine (OPV)-is among the most consequential achievements of prophylactic medicine of the past century. Each with their own strengths and weaknesses, they were used over the past 50 years in different settings and different regimens and combinations. This resulted in virtual elimination of the disease in almost the entire world with the exception of a few countries. Continuation of the eradication campaign coordinated by WHO may soon result in complete cessation of wild poliovirus transmission, and poliovirus may join smallpox virus in the club of extinct pathogens. However, unlike smallpox vaccination that was stopped after the interruption of virus circulation, vaccination against poliomyelitis will have to continue into the foreseeable future, due to significant differences in the nature and epidemiology of the viruses. This chapter reviews the reasons for the need to maintain high population immunity against polioviruses, makes the case for developing a new generation of polio vaccines, and discusses their desirable properties as well as new vaccine technologies that could be used to create polio vaccines for the post-eradication environment.

show abstract

“…Этот факт лежит в основе предположе-ния о том, что внутрикожное введение антигенов более эффективно по сравнению с внутримышеч-ным. В ходе клинических испытаний внутрикожного введения дробной дозы ИПВ было показано, что это действительно так, однако минимальная доза, необходимая для создания иммунитета, оказа-лась выше предполагаемой 1/5 внутримышечной дозы [125][126][127][128]. Эффективность первичной им-мунизации одной внутрикожной дозой ИПВ была доказана наличием вторичного иммунного ответа на бустерную дозу вакцины [129].…”

Section: новое поколение полиовакцинunclassified